---
title: "MHRA approves new treatment for severe alopecia areata"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/278894000.md"
description: "The MHRA has approved deuruxolitinib, branded as Leqselvi, for treating severe alopecia areata in adults. This new treatment option targets the autoimmune condition that causes hair loss by inhibiting specific enzymes involved in inflammation. The approval follows clinical trials with 1,223 participants, showing significant hair regrowth in those treated with Leqselvi. Approximately 30% of subjects achieved 80% scalp hair coverage after 24 weeks. The medication is available by prescription, with a recommended dosage of 8 mg taken twice daily. The MHRA will continue to monitor its safety and effectiveness."
datetime: "2026-03-12T13:26:33.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278894000.md)
  - [en](https://longbridge.com/en/news/278894000.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278894000.md)
---

# MHRA approves new treatment for severe alopecia areata

The MHRA has approved deuruxolitinib, marketed as Leqselvi, for the treatment of severe alopecia areata in adults, offering a new therapeutic option for people living with the autoimmune condition.

Alopecia areata occurs when the immune system attacks hair follicles, triggering inflammation that leads to hair loss on the scalp, face or other parts of the body.

Deuruxolitinib works by reducing the activity of JAK1, JAK2 and TYK2 relative to JAK3 kinases, enzymes involved in the inflammatory process at the hair follicle. By dampening this inflammation, the medicine can support hair regrowth.

Julian Beach, MHRA Executive Director, Healthcare Quality and Access, said: “This approval gives adults with alopecia areata another potential treatment option to help manage their condition. As with any medicine, the MHRA will keep the safety and effectiveness of deuruxolitinib under close review.”

Leqselvi is available only on prescription. The recommended dose is an 8 mg tablet taken twice daily.

The approval is based on two pivotal clinical trials involving 1223 adults who had lost at least 50 percent of their hair for more than six months. Participants received either Leqselvi 8 mg, deuruxolitinib 12 mg or a placebo twice daily for 24 weeks.

Those treated with Leqselvi achieved higher scores on a standard measure of scalp hair coverage compared with placebo.

After 24 weeks, around 30 percent of subjects experienced 80 percent or more scalp hair, while around 23 percent achieved 90 percent or more. The results indicate that deuruxolitinib can significantly improve hair growth in people with severe alopecia areata.

### Related Stocks

- [4528.JP](https://longbridge.com/en/quote/4528.JP.md)
- [API.AU](https://longbridge.com/en/quote/API.AU.md)

## Related News & Research

- [First healthy volunteers receive TRIV-573 doses in Triveni Bio’s Phase I trial](https://longbridge.com/en/news/286888745.md)
- [13:53 ETHouston-Based Founder Dr. Bre Hayward Expands Multicultural Haircare Brand "Baby Hair®" Under Phase Theory Beauty Co™](https://longbridge.com/en/news/287258308.md)
- [07:32 ETSamson Clinical Announces Last Patient Last Visit in its Pivotal Phase III Study of Sublingual Minoxidil for Male Androgenetic Alopecia](https://longbridge.com/en/news/286763418.md)
- [EMV Capital’s AMR Bio pushes XF-73 antimicrobial towards Phase 3 in major infection markets](https://longbridge.com/en/news/287166013.md)
- [MHRA to open new Northern Ireland hub to strengthen UK‑wide life sciences collaboration](https://longbridge.com/en/news/286240354.md)